Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 25.
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 25.
TRIAVIL 2-10 vs TRIAVIL 4-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-10 is a fixed-dose combination of amitriptyline (a tricyclic antidepressant) and perphenazine (a phenothiazine antipsychotic). Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic activity in the mesolimbic pathway.
TRIAVIL (amitriptyline/perphenazine) combines a tricyclic antidepressant (amitriptyline) that inhibits reuptake of norepinephrine and serotonin, and a phenothiazine antipsychotic (perphenazine) that blocks dopamine D2 receptors, serotonin 5-HT2 receptors, and alpha-adrenergic receptors, with additional anticholinergic, antihistaminergic, and antiemetic properties.
1 tablet (perphenazine 2 mg / amitriptyline 10 mg) orally 3 to 4 times daily. Maximum: perphenazine 64 mg/day, amitriptyline 300 mg/day.
One tablet (perphenazine 4 mg / amitriptyline 25 mg) orally 3 to 4 times daily. Maximum: 8 tablets daily.
None Documented
None Documented
Amitriptyline: 10-50 hours (mean 20h). Perphenazine: 8-21 hours (mean 12h). Clinically, steady state reached in 3-10 days; dose adjustments should consider accumulation.
Amitriptyline: 13–36 hours (mean ~21 hours); perphenazine: 8–21 hours (mean ~12 hours); steady-state achieved in 3–10 days.
Renal excretion accounts for approximately 50-60% of total clearance for amitriptyline (metabolites) and 20-30% for perphenazine (metabolites). Biliary/fecal elimination of metabolites contributes 10-20%.
Renal: ~70% as metabolites (including amitriptyline and perphenazine metabolites) and <5% unchanged; fecal: ~30% via bile; enterohepatic recirculation occurs.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination